Oestrogen Receptor Positive Breast Cancer
Oestrogen receptor positive (ER-positive) breast cancer is the most common breast cancer subtype worldwide, accounting for roughly two-thirds of all cases. The cancer cells carry receptors that bind oestrogen, which then signals them to grow. Blocking that signal is the cornerstone of treatment.
Medicine used to treat Oestrogen Receptor Positive Breast Cancer
How hormone therapy targets ER-positive tumours
Because oestrogen drives growth in these tumours, treatment focuses on cutting off its supply or blocking the receptor directly. Tamoxifen is the most established agent for this purpose: it binds the oestrogen receptor without activating it, starving the tumour of the growth signal it depends on. Tamoxifen is used in both early and advanced disease and has decades of evidence behind it. Broader support during and after treatment falls under oncology support.
Persistent side effects or any new lump, nipple change, or unexplained bone pain should be reviewed by an oncologist promptly.